Other
RIZIV
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
N/A
1(50.0%)
Phase 2
1(50.0%)
2Total
N/A(1)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT04747860Unknown
Predictors of Work Resumption After Back Surgery
Role: collaborator
NCT03996798Not ApplicableCompleted
Disability Case Manager: Full Member of the Revalidation Team
Role: collaborator
NCT01676779Phase 2Completed
mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma
Role: collaborator
All 3 trials loaded